The latest price target for Tryp Therapeutics Inc Ordinary Shares (OTC:TRYPF) was reported by Ladenburg Thalmann on January 5, 2023. The analyst firm set a price target for $1.50 expecting TRYPF to rise to within 12 months (a possible 2569.04% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Tryp Therapeutics Inc Ordinary Shares (OTC:TRYPF) was provided by Ladenburg Thalmann, and Tryp Therapeutics Inc Ordinary Shares reiterated their buy rating.

There is no last upgrade for Tryp Therapeutics Inc Ordinary Shares

There is no last downgrade for Tryp Therapeutics Inc Ordinary Shares.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tryp Therapeutics Inc Ordinary Shares, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tryp Therapeutics Inc Ordinary Shares was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.

While ratings are subjective and will change, the latest Tryp Therapeutics Inc Ordinary Shares (TRYPF) rating was a reiterated with a price target of $0.00 to $1.50. The current price Tryp Therapeutics Inc Ordinary Shares (TRYPF) is trading at is $0.06, which is within the analyst’s predicted range.